Harrisburg Area Community College, York
This paper explores the legalization of cannabis from a medical and economic standpoint. In a pro/con format I will research and analyze different facts and opinions on whether or not legalizing cannabis is in the best interest of the people and the government. As we progress into the future more and more states are hopping on the bandwagon. Not only are the people interested in the advancements from a medical standpoint but is allowing each state themselves to decide how it will be handled and taxed benefiting the local economy. While this is a vital step forward, the work to ensure that all seriously ill patients who can benefit from medical cannabis have reasonable access to it is not done. (blog.mpp.org/medical-marijuana/new-york-becomes-the-23rd-medical-marijuana-state/07072014)
In 1972, the US Congress placed marijuana in Schedule I of the Controlled Substances Act because they considered it to have "no accepted medical use." Since then, 22 of 50 US states and DC have legalized the medical use of marijuana.
Proponents of medical marijuana argue that it can be a safe and effective treatment for the symptoms of cancer, AIDS, multiple sclerosis, pain, glaucoma, epilepsy, and other conditions. They cite dozens of peer-reviewed studies, prominent medical organizations, major government reports, and the use of marijuana as medicine throughout world history.
Opponents of medical marijuana argue that it is too dangerous to use, lacks FDA-approval, and that various legal drugs make marijuana use unnecessary. They say marijuana is addictive, leads to harder drug use, interferes with fertility, impairs driving ability, and injures the lungs, immune system, and brain. They say that medical marijuana is a front for drug legalization and recreational use. (http://medicalmarijuana.procon.org/)
I would like to give a brief history of medical cannabis and the
References: “Front Matter." Marijuana and Medicine: Assessing the Science Base. Washington, DC: The National Academies Press, (1999.) R. Mechoulam et al. 2003. Cannabidiol: an overview of some pharmacological aspects. Neuroscience Letters 346: 61-64; J. McPartland and E. Russo. 2002. Cannabis and cannabis extracts: greater than the sum of their parts. Journal of Cannabis Therapeutics 1: 103-132; A. Zuardi and F Guimaraes. Cannabidiol as an anxiolytic and antipsychotic. In: M. Mathre (Ed): Cannabis in medical practice: a legal, historical and pharmacological overview of therapeutic use of marijuana. McFarland Press: 1997: 133-141. Content.time.com/time/health/article/0,8599,1931247,00.html/ ( Patrick Stack, with Claire Suddath, Wednesday, Oct. 21, 2009) http://www.whitehouse.gov/ondcp/marijuana(2014) http://blog.mpp.org/medical-marijuana/new-york-becomes-the-23rd-medical-marijuana-state/07072014/ /norml.org/library/marinol-vs.-natural-cannabis updated 2005 https://www.aclu.org/blog/criminal-law-reform/hundreds-economists-marijuana).